OLDSMAR, Fla., Oct. 15, 2009 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCBB:CCEL) (“Company”), one of the largest and most established leaders in stem cell innovation, today announced that it has signed an exclusive technology license agreement with Cryopraxis Cryobiology Ltd. (“Cryopraxis”), a privately-held global regenerative technology leader located in Rio De Janeiro, Brazil. The license agreement will allow Cryopraxis to market and manufacture proprietary C’elle(SM) menstrual stem cell technology including the processing and storage of menstrual stem cells (MenSCs) throughout Brazil. The exclusive technology license agreement with Cryopraxis is expected to provide Cryo-Cell with future royalty fees from the processing and annual storage of menstrual stem cells in Brazil.
